Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P25025

UPID:
CXCR2_HUMAN

ALTERNATIVE NAMES:
CDw128b; GRO/MGSA receptor; High affinity interleukin-8 receptor B; IL-8 receptor type 2

ALTERNATIVE UPACC:
P25025; Q8IUZ1; Q9P2T6; Q9P2T7

BACKGROUND:
The C-X-C chemokine receptor type 2, known under various names including CDw128b and IL-8 receptor type 2, is integral to the immune system's response to inflammation and infection. It achieves this through its high-affinity binding to interleukin-8 and related chemokines, triggering neutrophil activation and migration to sites of infection.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of C-X-C chemokine receptor type 2 could open doors to potential therapeutic strategies for treating WHIM syndrome 2 and other related immunodeficiencies. By elucidating the receptor's function in neutrophil mobilization and immune response, novel interventions can be developed to mitigate these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.